MGMT and central nervous system cancer: TMZ therapy had a significant impact on glioma patients with MGMT promoter methylation with a HR of 0.76 (0.21–2.899; p = 0.029) as compared to 3.78 HR (95%; 1.71–6.8); p = 0.70 for those who did not receive therapy achieving an independent prognostic significance as indicated in Table 4.